世界の胃腸膵臓神経内分泌腫瘍治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4240 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、胃腸膵臓神経内分泌腫瘍治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、ペプチド受容体放射性核種療法、その他）、用途別市場規模（病院、診療所、外来外科センター、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・胃腸膵臓神経内分泌腫瘍治療薬の市場動向 ・企業の競争状況、市場シェア ・胃腸膵臓神経内分泌腫瘍治療薬の種類別市場規模と予測2016-2027（化学療法、ペプチド受容体放射性核種療法、その他） ・胃腸膵臓神経内分泌腫瘍治療薬の用途別市場規模と予測2016-2027（病院、診療所、外来外科センター、その他） ・胃腸膵臓神経内分泌腫瘍治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・胃腸膵臓神経内分泌腫瘍治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・胃腸膵臓神経内分泌腫瘍治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・胃腸膵臓神経内分泌腫瘍治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・胃腸膵臓神経内分泌腫瘍治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Novartis、Pfizer、Fresenius Kabi、Teva Pharmaceuticals、Sun Pharma、Hutchison China MediTech Limited、Exelixis, Inc.、Tarveda Therapeutics） ・結論

Market Analysis and Insights: Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market
The global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market.

Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Scope and Market Size
Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chemotherapy
Peptide-Receptor Radionuclide Therapy
Others

Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis
Pfizer
Fresenius Kabi
Teva Pharmaceuticals
Sun Pharma
Hutchison China MediTech Limited
Exelixis, Inc.
Tarveda Therapeutics

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Peptide-Receptor Radionuclide Therapy
1.2.4 Others
1.3 Market by Application
1.3.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Perspective (2016-2027)
2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Growth Trends by Regions
2.2.1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Industry Dynamic
2.3.1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Trends
2.3.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers
2.3.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges
2.3.4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue
3.1.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue
3.4 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio
3.4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2020
3.5 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players Head office and Area Served
3.6 Key Players Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Solution and Service
3.7 Date of Enter into Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Type
4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2022-2027)

5 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Application
5.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2016-2027)
6.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type
6.2.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2027)
6.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application
6.3.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2027)
6.4 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country
6.4.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2016-2027)
7.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type
7.2.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2027)
7.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application
7.3.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2027)
7.4 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country
7.4.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type
8.2.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application
8.3.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region
8.4.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2016-2027)
9.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type
9.2.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application
9.3.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country
9.4.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type
10.2.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application
10.3.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country
10.4.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.1.4 Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.2.4 Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Fresenius Kabi
11.3.1 Fresenius Kabi Company Details
11.3.2 Fresenius Kabi Business Overview
11.3.3 Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.3.4 Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
11.3.5 Fresenius Kabi Recent Development
11.4 Teva Pharmaceuticals
11.4.1 Teva Pharmaceuticals Company Details
11.4.2 Teva Pharmaceuticals Business Overview
11.4.3 Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.4.4 Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
11.4.5 Teva Pharmaceuticals Recent Development
11.5 Sun Pharma
11.5.1 Sun Pharma Company Details
11.5.2 Sun Pharma Business Overview
11.5.3 Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.5.4 Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
11.5.5 Sun Pharma Recent Development
11.6 Hutchison China MediTech Limited
11.6.1 Hutchison China MediTech Limited Company Details
11.6.2 Hutchison China MediTech Limited Business Overview
11.6.3 Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.6.4 Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
11.6.5 Hutchison China MediTech Limited Recent Development
11.7 Exelixis, Inc.
11.7.1 Exelixis, Inc. Company Details
11.7.2 Exelixis, Inc. Business Overview
11.7.3 Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.7.4 Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
11.7.5 Exelixis, Inc. Recent Development
11.8 Tarveda Therapeutics
11.8.1 Tarveda Therapeutics Company Details
11.8.2 Tarveda Therapeutics Business Overview
11.8.3 Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.8.4 Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
11.8.5 Tarveda Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Peptide-Receptor Radionuclide Therapy
Table 4. Key Players of Others
Table 5. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Regions (2022-2027)
Table 11. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Trends
Table 12. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers
Table 13. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges
Table 14. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints
Table 15. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2020)
Table 18. Ranking of Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Solution and Service
Table 22. Date of Enter into Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. Novartis Company Details
Table 63. Novartis Business Overview
Table 64. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 65. Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
Table 66. Novartis Recent Development
Table 67. Pfizer Company Details
Table 68. Pfizer Business Overview
Table 69. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 70. Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Fresenius Kabi Company Details
Table 73. Fresenius Kabi Business Overview
Table 74. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 75. Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Fresenius Kabi Recent Development
Table 77. Teva Pharmaceuticals Company Details
Table 78. Teva Pharmaceuticals Business Overview
Table 79. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 80. Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
Table 81. Teva Pharmaceuticals Recent Development
Table 82. Sun Pharma Company Details
Table 83. Sun Pharma Business Overview
Table 84. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 85. Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
Table 86. Sun Pharma Recent Development
Table 87. Hutchison China MediTech Limited Company Details
Table 88. Hutchison China MediTech Limited Business Overview
Table 89. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 90. Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
Table 91. Hutchison China MediTech Limited Recent Development
Table 92. Exelixis, Inc. Company Details
Table 93. Exelixis, Inc. Business Overview
Table 94. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 95. Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
Table 96. Exelixis, Inc. Recent Development
Table 97. Tarveda Therapeutics Company Details
Table 98. Tarveda Therapeutics Business Overview
Table 99. Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Tarveda Therapeutics Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Features
Figure 3. Peptide-Receptor Radionuclide Therapy Features
Figure 4. Others Features
Figure 5. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Ambulatory Surgical Centers Case Studies
Figure 9. Others Case Studies
Figure 10. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Report Years Considered
Figure 11. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Regions: 2020 VS 2027
Figure 14. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Regions (2022-2027)
Figure 15. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Players in 2020
Figure 16. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2020
Figure 18. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2016-2021)
Figure 19. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2022-2027)
Figure 20. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2016-2027)
Figure 22. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2016-2027)
Figure 23. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2016-2027)
Figure 24. United States Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2016-2027)
Figure 28. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2016-2027)
Figure 29. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2016-2027)
Figure 30. Germany Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2016-2027)
Figure 40. China Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2016-2027)
Figure 48. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2016-2027)
Figure 49. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2016-2027)
Figure 50. Mexico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2016-2027)
Figure 56. Turkey Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Novartis Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
Figure 61. Fresenius Kabi Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
Figure 62. Teva Pharmaceuticals Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
Figure 63. Sun Pharma Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
Figure 64. Hutchison China MediTech Limited Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
Figure 65. Exelixis, Inc. Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
Figure 66. Tarveda Therapeutics Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

---